Biovie Inc Quick Ratio (BIVI) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biovie Inc   (NASDAQ: BIVI)

Biovie Inc 's Quick Ratio

BIVI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2026, Quick Ratio fell to 2.37 below Biovie Inc average.

Within Major Pharmaceutical Preparations industry 266 other companies have achieved higher Quick Ratio than Biovie Inc in fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 573, from total ranking in the third quarter 2026 at 696.

Explain Quick Ratio?
How much Cash & cash equivalents BIVI´s has?
What are BIVI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BIVI Quick Ratio (Jun 30 2026)
Q4		 (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4
Y / Y Current Liabilities Change 72.51 % -34.92 % -76.47 % -77.09 % -76.47 %
Y / Y Cash & cash equivalent Change -48.83 % -43.42 % -26.42 % 24.75 % -26.42 %
Quick Ratio MRQ 2.37 8.13 7.97 15.95 7.97
BIVI's Total Ranking # 573 # 696 # 332 # 637 # 568
Seq. Current Liabilities Change 135.57 % -26.77 % 40.47 % -28.81 % -11.13 %
Seq. Cash & cash equivalent Change -31.47 % -25.34 % -29.76 % 42.37 % -24.22 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 267
Healthcare Sector # 459
Overall Market # 1277


Quick Ratio Statistics
High Average Low
138.1 8.6 0
(Mar 31 2014)   (Mar 31 2020)




Financial Statements
Biovie Inc 's Current Liabilities $ 4 Millions Visit BIVI's Balance sheet
Biovie Inc 's Cash & cash equivalent $ 9 Millions Visit BIVI's Balance sheet
Source of BIVI's Sales Visit BIVI's Sales by Geography


Cumulative Biovie Inc 's Quick Ratio

BIVI's Quick Ratio for the trailling 12 Months

BIVI Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -56.04 % -72.95 % -77.8 % -63.87 % -57.88 %
Y / Y Cash & cash equivalent TTM Growth -23.61 % -19.48 % -15.14 % -4.44 % -10.86 %
Quick Ratio TTM 7.04 9.65 9.86 5.74 4.05
Total Ranking TTM # 148 # 162 # 190 # 281 # 372
Seq. Current Liabilities TTM Growth 21.05 % -10.24 % -45.86 % -25.26 % -25.53 %
Seq. Cash & cash equivalent TTM Growth -11.71 % -12.08 % -7.04 % 5.86 % -6.93 %

Quick ratio ranking by company, industry and sector >> Back to BIVI Financial Strength Comparisons >> Go to Compare BIVI Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2026 to $3.80 millions, cumulative Quick Ratio decreased to 7.04 above the BIVI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 418 other companies have achieved higher Quick Ratio than Biovie Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending third quarter 2026 at 3339.

Explain Quick Ratio?
How much Cash & cash equivalents BIVI´s has?
What are BIVI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 419
Healthcare Sector # 852
Within the Market # 573


trailing twelve months Quick Ratio Statistics
High Average Low
9.52 2.19 0.01
(Dec 31 2025)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions

Date modified: 2026-09-02T19:07:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.